Prostate Cancer Daily

December 13, 2024

Videos

Peer-to-Peer Clinical Conversations

ARANOTE Study: Transforming Metastatic Hormone Sensitive Prostate Cancer Treatment - Fred Saad

Fred Saad

Fred Saad discusses the ARANOTE phase 3 study results, evaluating darolutamide plus ADT in metastatic hormone-sensitive prostate cancer.

View

PEACE-1 Trial Reveals Key Genomic Alterations Linked to Survival in Prostate Cancer Patients - Cédric Pobel

Cédric Pobel

Cédric Pobel discusses an ancillary study of the PEACE-1 trial, focusing on phenotypic and genomic characterization of de novo metastatic prostate cancer.

View

Beyond the Abstracts

Preclinical and Clinical Evidence for Using Perinatal Tissue Allografts in Nerve Sparing Robot Assisted Radical Prostatectomy to Hasten Recovery of Functional Outcomes: A Literature Review - Beyond the Abstract

A Phase I Trial of Image-Guided, Risk-Volume-Adapted Post-Prostatectomy Radiotherapy - Beyond the Abstract

Conference Coverage

ESMO 2024: TAMARACK: Randomized Phase 2 Trial of the B7-H3 Targeting Antibody Drug Conjugate Vobramitamab

ESMO 2024: SAABR: Single Arm Phase II Study of Androgen Receptor Pathway Inhibitor + Atezolizumab + GnRH analog and Stereotactic Body Radiotherapy to the Prostate in Men with De Novo Hormone-sensitive Metastatic Prostate Cancer

SUO 2024: Characteristics, Treatment Patterns, and Outcomes of African American Versus Caucasian Patients with Metastatic Castration-Resistant Prostate Cancer: Post Hoc Analysis of TRUMPET Registry

SUO 2024: Mevrometostat (PF-06821497) in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate: The Phase III Randomized Enz Study

SUO 2024: A Phase III Study of 177Lu-TLX591 plus Standard-of-Care Versus Standard-of-Care Alone in Patients with mCRPC (PROSTACT GLOBAL)

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Etiology of prostate cancer with the TMPRSS2:ERG fusion: A systematic review of risk factors.

AR alterations inform circulating tumor DNA detection in metastatic castration resistant prostate cancer patients.

Histopathologic Features and Transcriptomic Signatures Do Not Solve the Issue of Magnetic Resonance Imaging-Invisible Prostate Cancers: A Matched-Pair Analysis.

Stress testing deep learning models for prostate cancer detection on biopsies and surgical specimens.

Castrate-resistant prostate cancer response to taxane is determined by an HNF1-dependent apoptosis resistance circuit.

A Pilot Study of AI-Assisted Reading of Prostate MRI in Organized Prostate Cancer Testing - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Prostate Cancer Daily

Prostate Cancer

Login